光正眼科收盘上涨2.17%，最新市净率19.27，总市值21.98亿元

Group 1 - The core business of the company is focused on investment and management of ophthalmology hospitals, with main products including refractive projects, cataract projects, vision care services, and steel structure manufacturing and installation [1] - As of the first quarter of 2025, the company reported revenue of 208 million yuan, a year-on-year increase of 4.32%, and a net profit of 573,800 yuan, a year-on-year increase of 103.06%, with a gross profit margin of 37.61% [1] - The company's stock closed at 4.24 yuan, up 2.17%, with a latest price-to-book ratio of 19.27, marking a new low in 40 days, and a total market capitalization of 2.198 billion yuan [1] Group 2 - The company has three institutional investors holding a total of 137.3928 million shares, with a total market value of 541 million yuan [1] - The company's price-to-earnings ratio (TTM) is -14.15, while the industry average is 38.49, indicating a significant disparity [2] - The company's market capitalization stands at 2.198 billion yuan, compared to the industry median of 5.270 billion yuan [2]